Carlsmed (NASDAQ:CARL) Stock: Insider Jeffrey Bertolini Sells 747 Shares

Key Points

• Insider sale: COO Jeffrey Bertolini sold 747 Carlsmed shares at an average price of $14.39, reducing his holdings by 3.21% to 22,489 shares. He also sold 243 shares in a separate transaction on September 30.
• Stock and financial performance: CARL shares traded at $14.64, with a one-year range of $8.50 to $17.23. Carlsmed reported quarterly revenue of $18.94 million and an adjusted loss of $0.39 per share, while analysts expect a full-year loss of $1.50 per share.
• Analyst outlook remains positive: The stock has a consensus “Moderate Buy” rating and an average price target of $19.25, supported by four Buy ratings, one Hold, and one Sell recommendation.

Carlsmed, Inc. (NASDAQ:CARL - Get Free Report) COO Jeffrey Bertolini sold 747 shares of Carlsmed stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $14.39, for a total value of $10,749.33. Following the completion of the sale, the chief operating officer directly owned 22,489 shares in the company, valued at approximately $323,616.71. The trade was a 3.21% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Jeffrey Bertolini also recently made the following trade(s):

• On Wednesday, September 30th, Jeffrey Bertolini sold 243 shares of Carlsmed stock. The stock was sold at an average price of $13.99, for a total value of $3,399.57.

Carlsmed Price Performance

Shares of NASDAQ CARL traded down $0.66 during midday trading on Tuesday, reaching $14.64. 116,185 shares of the stock traded hands, compared to its average volume of 138,367. The company's 50 day moving average is $14.79 and its 200 day moving average is $12.14. Carlsmed, Inc. has a one year low of $8.50 and a one year high of $17.23. The company has a debt-to-equity ratio of 0.18, a current ratio of 8.84 and a quick ratio of 8.66. The stock has a market capitalization of $399.67 million, a PE ratio of -10.24 and a beta of 2.09.

Carlsmed (NASDAQ:CARL - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.01. Carlsmed had a negative net margin of 57.42% and a negative return on equity of 38.06%. The company had revenue of $18.94 million for the quarter. On average, equities research analysts anticipate that Carlsmed, Inc. will post -1.5 earnings per share for the current year.

Institutional Investors Weigh In On Carlsmed

Several institutional investors have recently made changes to their positions in CARL. BlackRock Inc. bought a new position in Carlsmed during the 2nd quarter valued at about $5,528,000. Janus Henderson Group PLC lifted its stake in Carlsmed by 7.6% in the first quarter. Janus Henderson Group PLC now owns 1,227,452 shares of the company's stock worth $11,108,000 after purchasing an additional 86,834 shares during the last quarter. KCM Capital Inc purchased a new position in shares of Carlsmed during the first quarter valued at approximately $1,810,000. Parkman Healthcare Partners LLC purchased a new position in shares of Carlsmed during the second quarter valued at approximately $6,200,000. Finally, Jupiter Topco LLC bought a new position in shares of Carlsmed during the second quarter valued at approximately $12,992,000.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on CARL. BTIG Research restated a "buy" rating and set a $23.00 target price on shares of Carlsmed in a research report on Monday, September 28th. Weiss Ratings raised Carlsmed from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Tuesday, August 11th. Wall Street Zen upgraded Carlsmed from a "sell" rating to a "hold" rating in a research report on Saturday, August 15th. Needham & Company LLC began coverage on Carlsmed in a research note on Wednesday, July 1st. They issued a "buy" rating and a $17.00 price objective for the company. Finally, Truist Financial lifted their target price on Carlsmed from $18.00 to $20.00 and gave the stock a "buy" rating in a report on Thursday, August 6th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Carlsmed has an average rating of "Moderate Buy" and a consensus price target of $19.25.

Carlsmed Company Profile

Carlsmed, Inc is a medical technology company focused on personalized solutions for spine surgery. The company develops patient-specific implants and digital planning tools intended to help surgeons address spinal deformity and degenerative conditions with procedures tailored to an individual patient's anatomy and surgical goals.

Its principal products are offered under the aprevo brand and include personalized interbody fusion implants produced using three-dimensional printing, along with software that supports implant design and preoperative planning.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.